EDSA vs ADMA vs NUVB vs KO vs JPM

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). ADMA Biologics, Inc. (ADMA) offers the better valuation at 13. 7x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate Edesa Biotech, Inc. (EDSA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 13. 7x versus The Coca-Cola Company at 27. 2x. On forward P/E, ADMA Biologics, Inc. is actually cheaper at 9. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +346. 2%, compared to -85. 6% for Edesa Biotech, Inc. (EDSA). Over 10 years, the gap is even starker: JPM returned +465. 8% versus EDSA's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Nuvation Bio Inc. 's 2. 23β — meaning NUVB is approximately -1212% more volatile than KO relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ADMA Biologics, Inc. (ADMA) trades at 9. 9x forward P/E versus 25. 3x for The Coca-Cola Company — 15. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 164. 2% to $13. 00.

In this comparison, KO (2.

5% yield), JPM (1. 9% yield) pay a dividend. EDSA, ADMA, NUVB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, NUVB: -50. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EDSA (Healthcare) and ADMA (Healthcare) and NUVB (Healthcare) and KO (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EDSA is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; NUVB is a small-cap high-growth stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock. KO, JPM pay a dividend while EDSA, ADMA, NUVB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.